KESHAV
New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years ASCO Publications
Author's Disclosures of Potential Conflicts of Interest New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 Years If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu. Purchase full access to this article.
Estes produtos foram associados automaticamente a partir do titulo, resumo e conteudo do artigo.
The system matched these relevant products from the article content: LORLADX Lorlatinib Lucius Lorlatinib – Compre online LORLADX Lorlatinib 100mg.
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
